From the Editor

Industry professionals share the ups and downs of working in the biopharma industry.

Ebola Virus Disease (EVD) is a severe, often fatal disease that is transmitted human-to-human through bodily fluids.

FDA draft guidances seek to maintain accurate drug information in new media.

Changes are needed to maintain US biopharma innovation leadership.

More media options open publishing opportunities for bioprocessing experts and authors.

ISPE and PDA take on the challenge of recommending quality metrics.

Generics, market dynamics, and global demand are changing drug spending patterns.

Higher wages and employment rates give biopharm professionals an edge over counterparts in other industries.

The JOBS Act and FDASIA show early signs of accelerating drug development.

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.

Pharma and biotech companies, with the rest of the healthcare industry, must face change.

Ranbaxy's $500 million settlement for producing adulterated drugs and fradulent data provides a cautionary tale for patients, FDA, and drug manufacturers.

Wanted: Aspiring authors to share technical and scientific solutions for biopharmaceutical processing.

A QbD paradigm advances process understanding in development and manufacturing.

Our editorial advisory board members provide their perspective on what's ahead in the biopharmaceutical industry.

Keeping tabs on crucial medicines should be part of consumers' and manufacturers' emergency-preparedness plans.

Global coordination tactics that incorporate online technologies and social media are reshaping disease prevention and response.

Will the next US President support the backbone of our industry?

Although FDA cannot do anything to stop drugs from being discontinued, it can do something about supply and quality problems that lead to shortages.

No matter the time or cost, knowing what's going on inside your facilities is always going to be worth the effort.

Has the long-awaited guidance answered all of the industry's questions?

Industry announces plans for year ahead at annual JPMorgan Global Healthcare Conference.

The benefits of harmonization may be on industry's wish list, but buying into change is another story.

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.

A report commissioned by FDA evaluates the QbD paradigm.